A foreign pharmaceutical manufacturer sends a portfolio of 300 APIs to Bangladesh. The usual approach? Send the same list to 50 pharmaceutical companies, wait for inquiries, follow up, reduce the price, follow up again, and eventually conclude: “Bangladesh is a difficult market.”
But perhaps Bangladesh was never the problem. Perhaps the product selection was wrong.
Bangladesh manufactures roughly 98% of the medicines consumed domestically, yet the industry still depends heavily on imported APIs and raw materials. That creates an interesting contradiction:
A Tale of Two Molecules
Imagine evaluating two different Active Pharmaceutical Ingredients for market entry:
API A: The Red Ocean
- 40+ Bangladeshi companies market the molecule
- Multiple brands already compete
- Large formulation volume
- Several established API suppliers
- Buyers are highly price-sensitive
⚠️ Looks attractive due to customer count, but entry is extremely difficult due to supply maturity.
API B: The Strategic Gap
- Only 5–7 companies manufacture the formulation
- Requires stronger technical capability
- Fewer qualified suppliers available
- Therapeutic segment is expanding
- More local companies likely to enter later
✅ Current volume may be smaller, but long-term strategic opportunity is significantly higher.
Opportunity = Demand × Import Dependency × Customer Fit × Supply Gap × Entry Probability
Formulation vs. API Supply Competition
Suppose Bangladesh has 25 brands of Product X. Foreign manufacturers often interpret this as “the market is overcrowded.”
An API manufacturer should ask something completely different: “Who is supplying those 25 brands?”
Not every Bangladeshi pharmaceutical company is a realistic customer for every molecule. Target alignment depends entirely on therapeutic specialization:
The Portfolio Filtering Matrix
To convert catalog lists into actual revenue, market intelligence should move systematically through this funnel:
The Key Takeaway
Bangladesh is a sophisticated generic-manufacturing market with substantial dependence on imported APIs. That combination creates opportunity—but the opportunity is selective, not universal.
The biggest market is not always the best opportunity. The most popular molecule is not always the best product. Sometimes, the opportunity everyone overlooks is more valuable than the product everyone is already selling.
The Distribution of Pharmaceutical Demand Across Therapeutic Categories Offers an Important Signal for International Manufacturers Looking at Bangladesh
I quoted less than $600/ from my competitor, but the order closed at $2000/kg, So did they win? Behind the Reason-
Read More Articles
The Missing Strategy Behind Continuous pharma API Sales
Pharma API Business Development The Missing Strategy Behind Continuous Pharma API Sales A good product can win an order. But continuous sales require something more — a strategy for continuously developing the customer and the market. The real question is not only how...
The Desire of Every Business Director- “Sell”
More Articles
You Don’t Always Need an Office in Bangladesh. You Need the Right Market Partner
Read More Articles
Why Product Demand ≠ Market Opportunity
Cross-Functional Approval Matrix: The Strategic Evaluation Framework Every International API Manufacturer Should Understand
Read More Artcle
Why Approved Supplier Lists Matter in Manufacturing
Read More Articles
ICH Q6A: Chemical Substance Specifications and Test Procedures
Read More Articles
Tablet Granules Consistency & Density (Bulk and Tapped): Critical Quality Factors in Pharmaceutical Manufacturing
When a batch of pharmaceutical tablets fails in the compression room due to capping, lamination, or weight variation, the immediate reaction is often to adjust the machine settings or blame the rotary press. However, experienced production and QA teams know that the...









